Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
18.55
+1.05 (6.00%)
Aug 13, 2025, 4:00 PM - Market closed
Upstream Bio Employees
Upstream Bio had 52 employees as of December 31, 2024.
Employees
52
Change
n/a
Growth
n/a
Revenue / Employee
$52,365
Profits / Employee
-$2,116,519
Market Cap
1.00B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
UPB News
- 8 days ago - Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress - GlobeNewsWire
- 5 weeks ago - Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) - GlobeNewsWire
- 2 months ago - Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewsWire
- 2 months ago - Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 - GlobeNewsWire
- 2 months ago - Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Upstream Bio Appoints Stacy Price as Chief Technology Officer - GlobeNewsWire
- 3 months ago - Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs - GlobeNewsWire
- 4 months ago - Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent - Seeking Alpha